Advanced search
1 file | 342.66 KB Add to list

Use of the lung cancer-specific quality of life questionnaire EORTC QLQ-LC13 in clinical trials: a systematic review of the literature 20 years after its development

(2015) CANCER. 121(24). p.4300-4323
Author
Organization
Keywords
lung cancer, quality of life, clinical trials, outcome, PHASE-III TRIAL, MALIGNANT-PLEURAL-MESOTHELIOMA, SINGLE-AGENT GEMCITABINE, RANDOMIZED CONTROLLED-TRIALS, PLATINUM-BASED CHEMOTHERAPY, PATIENT-REPORTED OUTCOMES, CISPLATIN PLUS VINORELBINE, ACTIVE SYMPTOM CONTROL, LEUKEMIA GROUP-B, EUROPEAN-ORGANIZATION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 342.66 KB

Citation

Please use this url to cite or link to this publication:

MLA
Koller, Michael et al. “Use of the Lung Cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in Clinical Trials: a Systematic Review of the Literature 20 Years After Its Development.” CANCER 121.24 (2015): 4300–4323. Print.
APA
Koller, M., Warncke, S., Hjermstad, M. J., Arraras, J., Pompili, C., Harle, A., Johnson, C. D., et al. (2015). Use of the lung cancer-specific quality of life questionnaire EORTC QLQ-LC13 in clinical trials: a systematic review of the literature 20 years after its development. CANCER, 121(24), 4300–4323.
Chicago author-date
Koller, Michael, Sophie Warncke, Marianne J Hjermstad, Juan Arraras, Cecilia Pompili, Amelie Harle, Colin D Johnson, et al. 2015. “Use of the Lung Cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in Clinical Trials: a Systematic Review of the Literature 20 Years After Its Development.” Cancer 121 (24): 4300–4323.
Chicago author-date (all authors)
Koller, Michael, Sophie Warncke, Marianne J Hjermstad, Juan Arraras, Cecilia Pompili, Amelie Harle, Colin D Johnson, Wei-Chu Chie, Christian Schulz, Florian Zeman, Jan Van Meerbeeck, Dagmara Kuliś, and Andrew Bottomley. 2015. “Use of the Lung Cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in Clinical Trials: a Systematic Review of the Literature 20 Years After Its Development.” Cancer 121 (24): 4300–4323.
Vancouver
1.
Koller M, Warncke S, Hjermstad MJ, Arraras J, Pompili C, Harle A, et al. Use of the lung cancer-specific quality of life questionnaire EORTC QLQ-LC13 in clinical trials: a systematic review of the literature 20 years after its development. CANCER. 2015;121(24):4300–23.
IEEE
[1]
M. Koller et al., “Use of the lung cancer-specific quality of life questionnaire EORTC QLQ-LC13 in clinical trials: a systematic review of the literature 20 years after its development,” CANCER, vol. 121, no. 24, pp. 4300–4323, 2015.
@article{7147095,
  author       = {Koller, Michael and Warncke, Sophie and Hjermstad, Marianne J and Arraras, Juan and Pompili, Cecilia and Harle, Amelie and Johnson, Colin D and Chie, Wei-Chu and Schulz, Christian and Zeman, Florian and Van Meerbeeck, Jan and Kuliś, Dagmara and Bottomley, Andrew},
  issn         = {0008-543X},
  journal      = {CANCER},
  keywords     = {lung cancer,quality of life,clinical trials,outcome,PHASE-III TRIAL,MALIGNANT-PLEURAL-MESOTHELIOMA,SINGLE-AGENT GEMCITABINE,RANDOMIZED CONTROLLED-TRIALS,PLATINUM-BASED CHEMOTHERAPY,PATIENT-REPORTED OUTCOMES,CISPLATIN PLUS VINORELBINE,ACTIVE SYMPTOM CONTROL,LEUKEMIA GROUP-B,EUROPEAN-ORGANIZATION},
  language     = {eng},
  number       = {24},
  pages        = {4300--4323},
  title        = {Use of the lung cancer-specific quality of life questionnaire EORTC QLQ-LC13 in clinical trials: a systematic review of the literature 20 years after its development},
  url          = {http://dx.doi.org/10.1002/cncr.29682},
  volume       = {121},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: